Abstract 97P
Background
In the global LEAP-017 trial, treatment with lenvatinib + pembrolizumab (L + P) trended toward longer, but not significant, OS (HR: 0.83, 95% CI: 0.68-1.02, p-value: 0.0379) vs regorafenib or trifluridine–tipiracil (SOC), and toward more benefit in PFS and ORR. We present results of an exploratory analysis of patients (pts) enrolled in Asia combined with an extension cohort from China.
Methods
Eligible pts were aged ≥ 18 years, with confirmed unresectable, non-MSI-H/dMMR mCRC, and ≥1 prior line of therapy. Pts were allocated (1:1) to L (20 mg QD) + P (400 mg Q6W, up to 18 cycles) or SOC. Primary endpoint was OS. Secondary endpoints were PFS and ORR per RECIST 1.1 by BICR, and safety.
Results
At data cut-off (Feb 20, 2023), 237 pts were enrolled from Asia including China (N=100), Japan (N=63), Korea (N=41), and Taiwan (N=33). Overall, 118 pts received L + P, and 117 received SOC. In the Asia subgroup, after a median follow-up of 15.1 months (mo) and 15.2 mo, respectively, OS was longer with L + P vs SOC (median 13.4 vs 10.3 mo; HR: 0.63, 95% CI: 0.45-0.88), median PFS was 3.8 mo with L + P and 3.3 mo with SOC (HR: 0.78, 95% CI, 0.58-1.05), and ORR was 11.9% (95% CI, 6.6%- 19.1%) with L + P and 0% with SOC. In the China cohort, OS was longer with L + P vs SOC (median 14.9 vs 10.3 mo; HR: 0.61, 95% CI, 0.33-1.15), median PFS was 3.7 mo with L + P and 2.4 mo with SOC (HR: 1.18, 95% CI, 0.75-1.85), and ORR was 5.7% (95% CI, 1.2%-15.7%) with L + P and 0% with SOC. Grade ≥ 3 treatment-related AE rates were 58.5% and 49.6% with L + P and SOC, respectively, in the Asia subgroup, and 43.9% and 64.3%, respectively, in the Chinese extension cohort. One grade 5 treatment-related AE of pneumonitis occurred in the L + P arm in the Asia subgroup.
Conclusions
In this exploratory analysis from the Asia subgroup of LEAP-017 including the China extension, treatment with L + P vs SOC trended toward longer OS, consistent with the global trial. Trends towards improved PFS and ORR with L + P were also seen, consistent with the global trial; however, a similar trend in the PFS HR in the China subgroup was not observed. No new safety signals were observed.
Clinical trial identification
NCT04776148; first posted on February 26, 2021.
Editorial acknowledgement
Provided by Jose Casasvonas Nieves, PhD, an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Legal entity responsible for the study
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Funding
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Disclosure
R. Xu: Financial Interests, Personal, Invited Speaker: BMS, MSD; Financial Interests, Personal, Advisory Board: Henrui, BeiGene, Astellas, Merck, Junshi. H. Teng: Financial Interests, Personal, Advisory Role: MSD Taiwan; Financial Interests, Personal, Speaker’s Bureau: MSD Taiwan. A. Takashima: Financial Interests, Institutional, Research Funding: MSD. T. Yang: Financial Interests, Institutional, Research Funding: MSD. T.W. Kim: Financial Interests, Institutional, Research Grant: Genentech; Financial Interests, Institutional, Research Funding: Merck. T. Kim: Financial Interests, Personal, Ownership Interest: IMBdx; Financial Interests, Institutional, Research Funding: MSD. J.O. Park: Financial Interests, Personal, Advisory Board: MedPacto, BMS (Celgene), Servier, MediRama, Adicet Bio, AstraZeneca, Merck Sereno, ImmuneOncia, Merck; Financial Interests, Personal, Other, Travel support for a poster presentation at ASCO GI 2023: Minneamrita Therapeutics LLC; Financial Interests, Personal, Research Grant, Clinical research grant: MedPacto, Servier, BMS (Celgene); Financial Interests, Personal, Research Grant: Eutilex, ABL Bio. S. Lee: Financial Interests, Institutional, Research Funding: MSD. K. Yeh: Financial Interests, Personal, Advisory Board: Daiichi Sankyo, PhytoHealth, Novartis, Ono, Merck, AstraZeneca; Non-Financial Interests, Personal, Member: American Society of Clinical Oncology, American Association for Cancer Research. T. Yoshino: Financial Interests, Personal, Invited Speaker: Chugai Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., Bayer Yakuhin, Ltd., Ono Pharmaceutical Co., Ltd., MSD K.K., Takeda Pharmaceutical Co., Ltd.; Financial Interests, Personal, Other, Consultancy: Sumitomo Corp.; Financial Interests, Institutional, Research Grant: Ono Pharmaceutical Co., Ltd, Sanofi K.K., MSD K.K., Taiho Pharmaceutical Co., Ltd., Molecular Health GmbH, Amgen K.K., Pfizer Japan Inc., Genomedia Inc., Sysmex Corp., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Eisai Co., Ltd., Roche Diagnostics K.K., FALCO Biosystems Ltd. R. Fu, R. Jain, D.E. Adelberg: Financial Interests, Personal, Full or part-time Employment: Merck. A. Kawazoe: Financial Interests, Personal, Advisory Board: Zymeworks, Merck & Co.; Financial Interests, Personal, Invited Speaker: Taiho, Daiichi Sankyo, Eli Lilly, Bristol Myers Squibb, Ono, All other authors have declared no conflicts of interest.
Resources from the same session
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract